These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

309 related articles for article (PubMed ID: 32525580)

  • 1. L-DEP regimen salvage therapy for paediatric patients with refractory Epstein-Barr virus-associated haemophagocytic lymphohistiocytosis.
    Zhao Y; Li Z; Zhang L; Lian H; Ma H; Wang D; Zhao X; Zhang Q; Wang T; Zhang R
    Br J Haematol; 2020 Nov; 191(3):453-459. PubMed ID: 32525580
    [TBL] [Abstract][Full Text] [Related]  

  • 2. PEG-aspargase and DEP regimen combination therapy for refractory Epstein-Barr virus-associated hemophagocytic lymphohistiocytosis.
    Wang J; Wang Y; Wu L; Zhang J; Lai W; Wang Z
    J Hematol Oncol; 2016 Sep; 9(1):84. PubMed ID: 27613189
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [L-DEP regimen salvage therapy for refractory primary hemophagocytic lymphohistiocytosis triggered by Epstein-Barr virus infection in 4 children].
    Zhao YZ; Ma HH; Lian HY; Wang D; Wang TY; Zhang R
    Zhonghua Er Ke Za Zhi; 2024 May; 62(5):467-472. PubMed ID: 38623016
    [No Abstract]   [Full Text] [Related]  

  • 4. Epstein-Barr virus-associated hemophagocytic lymphohistiocytosis in adults and adolescents-a life-threatening disease: analysis of 133 cases from a single center.
    Lai W; Wang Y; Wang J; Wu L; Jin Z; Wang Z
    Hematology; 2018 Dec; 23(10):810-816. PubMed ID: 29957156
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Ruxolitinib combined with liposomal doxorubicin, etoposide, methylprednisolone+/-PEG-asparaginase in treatment of relapsed/refractory pediatric hemophagocytic lymphohistiocytosis].
    Wei A; Ma HH; Zhang LP; Lian HY; Du JY; Wang D; Cui L; Ou WX; Zhao YZ; Zhao XX; Zhang L; Li ZG; Wang TY; Zhang R
    Zhonghua Yi Xue Za Zhi; 2022 Jul; 102(28):2167-2172. PubMed ID: 35872580
    [No Abstract]   [Full Text] [Related]  

  • 6. [Clinical study of DEP regimen as a salvage therapy for adult refractory hemophagocytic lymphohistiocytosis].
    Wang Y; Huang W; Wei N; Zeng X; Zhang J; Wang J; Wu L; Fu L; Wang Z
    Zhonghua Xue Ye Xue Za Zhi; 2014 Oct; 35(10):901-4. PubMed ID: 25339326
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Haploidentical hematopoietic stem cell transplantation for adult patients with Epstein-Barr virus-associated hemophagocytic lymphohistiocytosis.
    Li Z; Wang Y; Wang J; Zhang J; Wang Z
    Leuk Lymphoma; 2018 Jan; 59(1):77-84. PubMed ID: 28573910
    [TBL] [Abstract][Full Text] [Related]  

  • 8. L-DEP regimen is effective as an initial therapy for adult EBV-HLH.
    Chen L; Wang J; Wang Z
    Ann Hematol; 2022 Nov; 101(11):2461-2470. PubMed ID: 36094533
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ruxolitinib-combined doxorubicin-etoposide-methylprednisolone regimen as a salvage therapy for refractory/relapsed haemophagocytic lymphohistiocytosis: a single-arm, multicentre, phase 2 trial.
    Wang J; Zhang R; Wu X; Li F; Yang H; Liu L; Guo H; Zhang X; Mai H; Li H; Wang Z
    Br J Haematol; 2021 May; 193(4):761-768. PubMed ID: 33559893
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Multicenter study of combination DEP regimen as a salvage therapy for adult refractory hemophagocytic lymphohistiocytosis.
    Wang Y; Huang W; Hu L; Cen X; Li L; Wang J; Shen J; Wei N; Wang Z
    Blood; 2015 Nov; 126(19):2186-92. PubMed ID: 26289641
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Short-term effectiveness of ruxolitinib in the treatment of recurrent or refractory hemophagocytic lymphohistiocytosis in children.
    Wei A; Ma H; Li Z; Zhang L; Zhang Q; Wang D; Lian H; Zhang R; Wang T
    Int J Hematol; 2020 Oct; 112(4):568-576. PubMed ID: 32666469
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Nivolumab treatment of relapsed/refractory Epstein-Barr virus-associated hemophagocytic lymphohistiocytosis in adults.
    Liu P; Pan X; Chen C; Niu T; Shuai X; Wang J; Chen X; Liu J; Guo Y; Xie L; Wu Y; Liu Y; Liu T
    Blood; 2020 Mar; 135(11):826-833. PubMed ID: 31914172
    [TBL] [Abstract][Full Text] [Related]  

  • 13. HLA-mismatched GPBSC infusion therapy in refractory Epstein-Barr virus-associated hemophagocytic lymphohistiocytosis: an observational study from a single center.
    Song Y; Wang J; Wang Y; Wang Z
    Stem Cell Res Ther; 2020 Jul; 11(1):265. PubMed ID: 32611452
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Sintilimab treatment for chronic active Epstein-Barr virus infection and Epstein-Barr virus-associated hemophagocytic lymphohistiocytosis in children.
    Chen R; Lin Q; Zhu Y; Shen Y; Xu Q; Tang H; Cui N; Jiang L; Dai X; Chen W; Li X
    Orphanet J Rare Dis; 2023 Sep; 18(1):297. PubMed ID: 37736751
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Outcome of L-DEP regimen for treatment of pediatric chronic active Epstein-Barr virus infection.
    Ma H; Zhang L; Wei A; Yang J; Wang D; Zhang Q; Zhao Y; Chen S; Lian H; Zhang L; Zhou C; Qin M; Li Z; Wang T; Zhang R
    Orphanet J Rare Dis; 2021 Jun; 16(1):269. PubMed ID: 34112210
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Treatment of Epstein Barr virus-induced haemophagocytic lymphohistiocytosis with rituximab-containing chemo-immunotherapeutic regimens.
    Chellapandian D; Das R; Zelley K; Wiener SJ; Zhao H; Teachey DT; Nichols KE;
    Br J Haematol; 2013 Aug; 162(3):376-82. PubMed ID: 23692048
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Haemophagocytic lymphohistiocytosis and Epstein-Barr virus: a complex relationship with diverse origins, expression and outcomes.
    El-Mallawany NK; Curry CV; Allen CE
    Br J Haematol; 2022 Jan; 196(1):31-44. PubMed ID: 34169507
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hematopoietic stem cell transplantation for familial hemophagocytic lymphohistiocytosis and Epstein-Barr virus-associated hemophagocytic lymphohistiocytosis in Japan.
    Ohga S; Kudo K; Ishii E; Honjo S; Morimoto A; Osugi Y; Sawada A; Inoue M; Tabuchi K; Suzuki N; Ishida Y; Imashuku S; Kato S; Hara T
    Pediatr Blood Cancer; 2010 Feb; 54(2):299-306. PubMed ID: 19827139
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The DEP regimen is superior to the HLH-1994 regimen as first-line therapy for lymphoma-associated haemophagocytic lymphohistiocytosis.
    Meng G; Wang Y; Wang J; Wang Z
    Leuk Lymphoma; 2021 Apr; 62(4):854-860. PubMed ID: 33225788
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ruxolitinib treatment for SR-aGVHD in patients with EBV-HLH undergoing allo-HSCT.
    Meng G; Wang J; Wang X; Wang Y; Wang Z
    Ann Hematol; 2020 Feb; 99(2):343-349. PubMed ID: 31879790
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.